ArticleProbiotics and antimicrobial proteins2026
Gut Microbiome and Fecal Metabolome Analysis Reveal Potential Non-Invasive Biomarkers For Acute Myocardial Infarction.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although the gut microbiome is recognized as crucial for human health, its combined effects with microbial metabolites on acute myocardial infarction (AMI) remain poorly understood. This study investigated gut microbiome composition using 16 S rRNA sequencing and untargeted LC-MS metabolomics profiles from 24 AMI patients and 24 healthy individuals to identify microbial biomarkers, metabolite signatures, and key functional pathways. No significant difference was observed in alpha diversity, whereas beta diversity differed significantly between AMI patients and controls. At the taxonomic level, Bacteroidota, Proteobacteria, Escherichia_Shigella, Collinsella, and Klebsiella were increased, while Firmicutes, Actinobacteriota, and Bifidobacterium were decreased in the AMI group compared with controls. Metabolomic profiling identified seven metabolites with strong discriminatory power for AMI, with area under the curve (AUC) values ranging from 0.91 to 0.99. Among these, S‑adenosyl‑L‑homocysteine, Cyanidin 3‑[6‑(4‑glucosylcoumaryl)sophoroside] 5‑glucoside, and 5‑Methyltetrahydrofolate were found to be upregulated, whereas Prostaglandin J2, Leukotriene A4, and 5‑HEPE were downregulated. Based on these findings, the upregulated metabolites S‑Adenosyl‑L‑homocysteine, Cyanidin 3‑[6‑(4‑glucosylcoumaryl)sophoroside] 5‑glucoside, 5‑Methyltetrahydrofolate, and the downregulated metabolites Prostaglandin J2, Leukotriene A4, and 5‑HEPE represent candidate non‑invasive biomarkers for AMI that warrant further validation. Functional pathway analysis highlighted pronounced disruptions in arginine biosynthesis and the folate-mediated one-carbon metabolism. Spearman correlation analysis showed that specific gut microbial taxa were significantly associated with clinical parameters and metabolites implicated in AMI-related pathways. These findings revealed distinct microbial and metabolic profiles in Chinese patients with AMI compared to healthy controls. Future research should investigate causal mechanisms and evaluate microbiota-targeted approaches for cardiovascular disease prevention and therapy.
Indexed as
Identifiers
42823565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.